North America Regenerative Medicine Market 2024–2033

Reports Description

As per the current market research conducted by the CMI Market Research Team, the North America Regenerative Medicine Market is expected to record a CAGR of 20.5% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 7.80 Billion. By 2032, the valuation is anticipated to reach USD 19.83 Billion.

Regenerative Medicine Market – Significant Growth Factors

The increasing prevalence of genetic disorders is a significant driver of market expansion. Increase in the cases associated with trauma are increasing rapidly. An increase in the investments made for the research and development of regenerative medicine is anticipated to have a positive impact on the market.

Some Main Factors Are:-

• Habitual conditions are on the rise leading to an increase in demand for regenerative medicine.

• Increased frequency of heritable diseases.

• Swell in trauma incidents.

• Traumatic incidents lead to more need for regenerative medicine in the market. Accidents and trauma are increasing demands.

• Increased investment in regenerative drug research and development.

• Different companies and philanthropists are investing in regenerative drugs so there is a great increase in production.

• Strong product channel for regenerative drug products.

• Earnings and fashionability of stem cell treatment.

• Rise in incidences of cancer, and diabetes.

• Increasing research & development activities in the field of medical sciences.

• Increasing geriatric population

The increasing use of stem cell technologies, gene treatments, and tissue engineering, as well as regenerative medicine’s technological developments, are the main drivers of the market’s expansion in North America.

According to the Heart Disease & Stroke Statistical Fact Sheet 2020, congenital heart abnormalities are predicted to affect at least 40,000 infants annually in the United States. In the first year of life, roughly 25% of these, or 2.4 (per 1,000 live births), require therapy.

Additionally, the Centers for Disease Control and Prevention (CDC) estimates that atrial fibrillation is prevalent in the United States at 12.1 million by the year 2030.

Regenerative Medicine Market – Mergers and Acquisitions

• Johnson & Johnson and Lineage Cell Rectifiers Johnson & Johnson completed the accession of Lineage Cell rectifiers in early 2021, which will help the company expand its presence in the regenerative drug field.

• Baxter International and Xygen Medical In February 2021, Baxter International blazoned its accession of Xygen Medical, a leading inventor of regenerative drug technologies.

• Vertex Medicinals and Mast Rectifiers In March 2021, Vertex Pharmaceuticals blazoned its accession of Mast Rectifiers, a biopharmaceutical company concentrated on regenerative drugs.

• Takeda Pharmaceuticals and TiGenix In April 2021, Takeda Pharmaceuticals blazoned its accession of TiGenix, a regenerative drug company concentrated on stem cell curatives.

• Novartis and Endocyte In May 2021, Novartis blazoned its accession of Endocyte, a biopharmaceutical company concentrated on developing regenerative drug treatments for cancer. Astellas Pharma and CellSight In June 2021, Astellas Pharma blazoned its accession of CellSight, a regenerative drug company concentrated on developing cell curatives.

• Cellectis and Tmunity in July 2021, Cellectis blazoned its accession of Tmunity, a regenerative drug company concentrated on developing cell curatives for cancer.

• Roche and Cell Design Labs In August 2021, Roche blazoned its accession of Cell Design Labs, a regenerative drug company concentrated on developing cell curatives for cancer.

• Medtronic and CartiHeal In September 2021, Medtronic blazoned its accession of CartiHeal, a regenerative drug company concentrated on developing cell curatives for orthopaedic operations.

• Novo Nordisk and TiGenix In October 2021, Novo Nordisk blazoned its accession of TiGenix, a regenerative drug company concentrated on developing stem cell curatives.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Regenerative Medicine Market – Significant Threats

• HIGH RELINQUISHMENT OF STEM CELL TECHNOLOGY: One of the most significant scientific advancements in this field is stem cell research. It is essential for research on tissue regeneration and regenerative medicine. It affects not only nerve regeneration but also the redesign of the entire organ and the creation of cardiovascular disease-related products. In the following five years, the market for stem cells is predicted to grow by three times. Additionally, it is anticipated that advances in stem cell research will hasten the creation of new products and spur the market for regenerative medicine. Cord blood, adult, and embryonic stem cells are among the sources of stem cells that have the potential to stimulate the market for regenerative medicine. The commercialization of stem cells in tissue has been pushed by new therapies made from stem cells.

• ARISING OPERATION OF NANOTECHNOLOGY: The ability of nanomaterials to prevent immunological reactions from the body during transplantation is one of their promising qualities. The neighbouring tissues are not harmed when these materials are used in tissue engineering and regenerative medicine procedures. Therefore, the market for regenerative medicine has enormous potential for nanotechnology.

• EXPENSIVE TREATMENT ASSOCIATED WITH REGENERATIVE MEDICINE: The high cost of tissue engineering and regenerative medicine restrains market expansion. Due to the monopolistic environment created by the limited supply of tissue engineering and regenerative medicine, the developing tissue engineering sector has difficulties. Because there is less competition among suppliers, these services result in cost increases.

• GROWTH IN NEED OF REGENERATIVE MEDICINE IN ORGAN TRANSPLANTATION: According to the Health Resources & Services Administration (HRSA) of the U.S. Department of Health, as of March 2022, there were over 106,005 patients who required organ transplants, and it is anticipated that 17 people would die every day without them. The most popular treatment is a kidney transplant, with patients needing kidneys making up 80% of the waiting list. Despite the government’s aggressive efforts to raise the number of donors, there is a rising need for organ transplants.

• HIGH COST OF REGENERATIVE MEDICINE TREATMENT: Organ failures and flaws in the United States cost more than $400 billion annually, demonstrating the market’s potential. However, due to high treatment costs, which must be regulated, the market for tissue engineering and regenerative medicine in emerging nations has seen a declining trend.

Report Scope

Category-Wise Insights

By Product

• Gene Therapies: To give cells new capabilities, gene therapy attempts to introduce genetic material into the cells. A safe gene transfer agent must be able to sustain the expression of the intended gene in a large enough population of cells to have a biological impact.

• Cell Therapies: (Regenerative Medicine) Produce healthy cells to replace disease-affected ones. It is possible to direct stem cells to differentiate into particular cells that can be employed in individuals to regenerate and restore tissues that have been harmed or impacted by illness.

• Tissue-Engineering: The goal of the discipline of tissue engineering is to create biological replacements that preserve, repair, and enhance tissue function.

By Application

• Wound Care: With the use of autologous stem cells, regenerative medicine has the potential to successfully treat both acute and chronic wounds brought on by diabetes and burns, heal wounds more quickly and completely without the need for additional surgery or tissue grafting, and avoid life-threatening complications like infection and amputation.

By End User

• Hospitals and Clinics: The segment of hospitals and clinics is expected to show significant growth as a result of the huge client base that is available in the North American market. The number of elderly people visiting a hospital or clinic suffering from complex and chronic diseases is rapidly rising.

By Material

• Biologically derived material: The segment of biologically derived material has generated maximum revenue due to a growth in the number of organ transplantation procedures. The pharmaceutical segment is presenting a good product pipeline which is expected to increase the market size of North America regenerative medicine market.

North America Regenerative Medicine Market – Regional Analysis

With a market share of 51.32% in 2022, the North American region dominated the global market for regenerative medicine. The significant market growth is attributable to the availability of public and private development financing, the existence of cutting-edge technological frameworks to assist the quick detection of chronic diseases and the high healthcare spending in the area.

In addition, the region has grown as a result of numerous ongoing clinical trials for regenerative medicine by important industry players. For the prevention of acute graft versus host disease in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT), Bristol Myers Squibb acquired U.S. FDA approval in December 2021 for Orencia.

Asia Pacific is anticipated to witness the fastest growth rate in the coming times. This growth is attributed to the rapid-fire relinquishment of cell-grounded approaches in healthcare, the rising senior population in the region, and the emergence of crucial players.

In recent times, China has surfaced with rapid-fire expansion in structure and installations to accelerate stem cell exploration. This, in turn, is anticipated to fuel the growth of regenerative drugs in the region.   Geographically, North America dominates the regenerative medicine market due to a high prevalence of chronic diseases and an advanced healthcare system.

On the other hand, the Asia-Pacific region is predicted to have strong expansion due to rising healthcare costs and expanding investments by significant manufacturers in the development of new goods. Given that the majority of the medicines are still in the third phase of clinical trials, the regenerative medicine market is currently expanding and is anticipated to show significant promise in the next years.

This demonstrates how businesses have gotten involved in the commercialization of items for regenerative medicine. Government authorities’ interest in supplying the expanding demand for regenerative products is demonstrated by favorable regulatory and reimbursement regulations for tissue engineering.

Due to ethical concerns and debates surrounding its source, however, strong regulatory laws related to stem cell technology have presented significant obstacles to the acceptance of embryonic stem cells, consequently limiting the market’s expansion.

These difficulties should be overcome in the future when businesses and research institutions develop novel medicines that are projected to take the role of embryonic stem cells in a variety of applications. Additionally, the market is expected to develop as a result of emerging technologies, the use of stem cells, and technology innovation for tissue and organ transplantation.

The U.S. is the North American country that has contributed the most to the market expansion, followed by Canada as a productive place and Mexico as a country with a strong R&D infrastructure.

With a market share of 51.32% in 2022, the North American region dominated the global market for regenerative medicine. The significant market growth is attributable to the availability of public and private development financing, the existence of cutting-edge technological frameworks to assist the quick detection of chronic diseases and the high healthcare spending in the area.

In addition, the region has grown as a result of numerous ongoing clinical trials for regenerative medicine by important industry players. For the prevention of acute graft versus host disease in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT), Bristol Myers Squibb acquired U.S. FDA approval in December 2021 for Orencia.

Asia Pacific is anticipated to witness the fastest growth rate in the coming times. This growth is attributed to the rapid-fire relinquishment of cell-grounded approaches in healthcare, the rising senior population in the region, and the emergence of crucial players. In recent times, China has surfaced with rapid-fire expansion in structure and installations to accelerate stem cell exploration. This, in turn, is anticipated to fuel the growth of regenerative drugs in the region.

Geographically, North America dominates the regenerative medicine market due to a high prevalence of chronic diseases and an advanced healthcare system. On the other hand, the Asia-Pacific region is predicted to have strong expansion due to rising healthcare costs and expanding investments by significant manufacturers in the development of new goods.

Given that the majority of the medicines are still in the third phase of clinical trials, the regenerative medicine market is currently expanding and is anticipated to show significant promise in the next years. This demonstrates how businesses have gotten involved in the commercialization of items for regenerative medicine.

Government authorities’ interest in supplying the expanding demand for regenerative products is demonstrated by favorable regulatory and reimbursement regulations for tissue engineering. Due to ethical concerns and debates surrounding its source, however, strong regulatory laws related to stem cell technology have presented significant obstacles to the acceptance of embryonic stem cells, consequently limiting the market’s expansion.

These difficulties should be overcome in the future when businesses and research institutions develop novel medicines that are projected to take the role of embryonic stem cells in a variety of applications. Additionally, the market is expected to develop as a result of emerging technologies, the use of stem cells, and technology innovation for tissue and organ transplantation.

The U.S. is the North American country that has contributed the most to the market expansion, followed by Canada as a productive place and Mexico as a country with a strong R&D infrastructure.

The Global Regenerative Medicine request is largely competitive, with a large number of manufacturers and retailers operating encyclopaedically. Some of the crucial players in the Global Regenerative Medicine request include:

• Integra Life sciences
• Organogenesis Inc.
• Osiris Therapeutics (Smith & Nephew)
• Abbvie Inc. (Allergan Plc.)
• Cook Medical (Cook Biotech Incorporated)
• Others

The North America Regenerative Medicine Market is segmented as follows:

By Product

• Gene Therapies
• Cell Therapies
• Tissue-Engineering
• Small Molecules & Biologics

By Material

• Synthetic material
  • Biodegradable synthetic polymers
  • Scaffold
  • Artificial Vascular Graft
  • Materials Hydrogel Material
• Biologically derived material
  • Collagen
  • Xenogeneic material
• Genetically Engineered Material
  • Deoxyribonucleic Acid Transfection Vectors
  • Genetically Manipulated Cell
  • Three-Dimensional Polymer Technology
  • Transgenics
  • Fibroblast
  • Neural Stem Cell
  • Gene-Activated Matrices
• Pharmaceutical
  • Biologics
  • Small Molecules

By Application

• Wound Care
• Musculoskeletal
• Ophthalmology
• Oncology
• Cardiovascular
• Dermatology
• Neurology
• Others

By End User

• Hospitals & Clinics
• Commercial Industries
• Government & Academic Research Institutes

On the basis of North America Geography

• U.S
• Canada
• Mexico
• Rest of North America